About F-Star

We are an innovation focused biotech company dedicated to delivering next-generation multispecific antibody therapeutics so more people with cancer and other serious diseases can live longer and improved lives.

Our clinically validated multispecific antibody platform has delivered a deep proprietary and partnered pipeline of promising clinical and preclinical drug product candidates.

The “plug-and-play” format of our Fcab® and mAb technology platforms enables rapid discovery of differentiated drug product candidates with a natural human antibody format that allows for a straightforward manufacturing process, favourable safety profile and strong biological potency.

In 2023, F-star was acquired by invoX Pharma, a fully integrated biopharmaceutical company, wholly owned by Sino Biopharm.

Leadership

Our executive leadership team members have extensive experience in immuno-oncology and have worked with global pharmaceutical companies as well as biotechs, with a well-established track record of building biotech companies and developing biologics.

Neil Brewis

Head of F-star and CSO

Neil Brewis

Head of F-star and CSO

Over 25 years of experience in antibody engineering and drug R&D and has successfully advanced novel platforms from inception to clinical proof of concept, with a therapeutic focus in oncology. Formerly at GSK and Domantis Ltd.

Andrew Aitken

Head of IT, Data & Business Assurance

Andrew Aitken

Head of IT, Data & Business Assurance

Michelle Morrow

SVP, Head of Research

Michelle Morrow

SVP, Head of Research

Rosie Almond

Head of HR

Rosie Almond

Head of HR

Pauline Stevens

Head of Business Operations

Pauline Stevens

Head of Business Operations

Lara Boyd

VP, Head of BD & Corporate Strategy

Lara Boyd

VP, Head of BD & Corporate Strategy

Carys Jones

Head of Finance

Carys Jones

Head of Finance

Pharmaceutical Partnerships

F-star’s platform has been validated through partnerships for over a decade. We have collaboration and licensing agreements with many leading biopharma companies to research, develop, and commercialize therapies leveraging our modular antibody technology and mAb2 programs.  Our partners are targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS, among others.

Meet F-star Team Members

Ryan Fiehler, Ph.D.

Director, Discovery

Raffaella Giambalvo

Scientist

Matthew Lakins, Ph.D.

Director, Biology

Theo Levine

Laboratory Scientist Apprentice

Martyn Rhoades

Manager, In vivo Operations

Christel Veyssier

Director, Protein Sciences